We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas.
- Authors
Furu, M; Kajita, Y; Nagayama, S; Ishibe, T; Shima, Y; Nishijo, K; Uejima, D; Takahashi, R; Aoyama, T; Nakayama, T; Nakamura, T; Nakashima, Y; Ikegawa, M; Imoto, S; Katagiri, T; Nakamura, Y; Toguchida, J
- Abstract
Spindle cell sarcomas consist of tumors with different biological features, of which distant metastasis is the most ominous sign for a poor prognosis. However, metastasis is difficult to predict on the basis of current histopathological analyses. We have identified actin filament-associated protein 1-like 1 (AFAP1L1) as a candidate for a metastasis-predicting marker from the gene expression profiles of 65 spindle cell sarcomas. A multivariate analysis determined that AFAP1L1 was an independent factor for predicting the occurrence of distant metastasis (P=0.0001), which was further confirmed in another set of 41 tumors by a quantitative mRNA expression analysis. Immunohistochemical staining using paraffin-embedded tumor tissues revealed that the metastasis-free rate was significantly better in tumors negative for AFAP1L1 (P=0.0093 by log-rank test). Knocking down the AFAP1L1 gene in sarcoma cells resulted in inhibition of the cell invasion, and forced expression of AFAP1L1 in immortalized human mesenchymal stem cells induced anchorage-independent growth and increased cell invasiveness with high activity levels of matrix metallopeptidase. Furthermore, tumor growth in vivo was accelerated in AFAP1L1-transduced sarcoma cell lines. These results suggest that AFAP1L1 has a role in the progression of spindle cell sarcomas and is a prognostic biomarker.
- Subjects
BIOMARKERS; SARCOMA; TUMOR growth; METASTASIS; DIAGNOSTIC immunohistochemistry; PROTEIN genetics; ACTIN; GENE expression; MULTIVARIATE analysis
- Publication
Oncogene, 2011, Vol 30, Issue 38, p4015
- ISSN
0950-9232
- Publication type
Article
- DOI
10.1038/onc.2011.108